Concurrent inhibition of neurosphere and monolayer cells of pediatric glioblastoma by aurora a inhibitor mln8237 predicted survival extension in pdox models

Mari Kogiso, Lin Qi, Frank K. Braun, Sarah G. Injac, Linna Zhang, Yuchen Du, Huiyuan Zhang, Frank Y. Lin, Sibo Zhao, Holly Lindsay, Jack M. Su, Patricia A. Baxter, Adekunle M. Adesina, Debra Liao, Mark G. Qian, Stacey Berg, Jodi A. Muscal, Xiao Nan Li*

*Corresponding author for this work

Research output: Contribution to journalArticle

4 Scopus citations

Abstract

Purpose: Pediatric glioblastoma multiforme (pGBM) is a highly aggressive tumor in need of novel therapies. Our objective was to demonstrate the therapeutic efficacy of MLN8237 (alisertib), an orally available selective inhibitor of Aurora A kinase (AURKA), and to evaluate which in vitro model system (monolayer or neurosphere) can predict therapeutic efficacy in vivo. Experimental Design: AURKA mRNA expressions were screened with qRT-PCR. In vitro antitumor effects were examined in three matching pairs of monolayer and neurosphere lines established from patient-derived orthotopic xenograft (PDOX) models of the untreated (IC-4687GBM), recurrent (IC-3752GBM), and terminal (IC-R0315GBM) tumors, and in vivo therapeutic efficacy through log rank analysis of survival times in two models (IC-4687GBM and IC-R0315GBM) following MLN8237 treatment (30 mg/kg/day, orally, 12 days). Drug concentrations in vivo and mechanism of action and resistance were also investigated. Results: AURKA mRNA overexpression was detected in 14 pGBM tumors, 10 PDOX models, and 6 cultured pGBM lines as compared with 11 low-grade gliomas and normal brains. MLN8237 penetrated into pGBM xenografts in mouse brains. Significant extension of survival times were achieved in IC-4687GBM of which both neurosphere and monolayer were inhibited in vitro, but not in IC-R0315GBM of which only neurosphere cells responded (similar to IC-3752GBM). Apoptosis-mediated MLN8237 induced cell death, and the presence of AURKA-negative and CD133 þ cells appears to have contributed to in vivo therapy resistance. Conclusions: MLN8237 successfully targeted AURKA in a subset of pGBMs. Our data suggest that combination therapy should aim at AURKA-negative and/or CD133 þ pGBM cells to prevent tumor recurrence.

Original languageEnglish (US)
Pages (from-to)2159-2170
Number of pages12
JournalClinical Cancer Research
Volume24
Issue number9
DOIs
StatePublished - May 1 2018

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Concurrent inhibition of neurosphere and monolayer cells of pediatric glioblastoma by aurora a inhibitor mln8237 predicted survival extension in pdox models'. Together they form a unique fingerprint.

  • Cite this

    Kogiso, M., Qi, L., Braun, F. K., Injac, S. G., Zhang, L., Du, Y., Zhang, H., Lin, F. Y., Zhao, S., Lindsay, H., Su, J. M., Baxter, P. A., Adesina, A. M., Liao, D., Qian, M. G., Berg, S., Muscal, J. A., & Li, X. N. (2018). Concurrent inhibition of neurosphere and monolayer cells of pediatric glioblastoma by aurora a inhibitor mln8237 predicted survival extension in pdox models. Clinical Cancer Research, 24(9), 2159-2170. https://doi.org/10.1158/1078-0432.CCR-17-2256